Last reviewed · How we verify
Hyperinsulinemic euglycemic clamp
The hyperinsulinemic euglycemic clamp is a research methodology that measures insulin sensitivity by infusing insulin while maintaining blood glucose at a constant level.
At a glance
| Generic name | Hyperinsulinemic euglycemic clamp |
|---|---|
| Also known as | HEC, Whole-body insulin sensitivity measurement |
| Sponsor | AdventHealth Translational Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is not a drug but a standardized clinical research technique used to quantify whole-body insulin sensitivity and glucose utilization. During the procedure, insulin is infused intravenously at a constant rate while blood glucose is maintained at basal levels through variable glucose infusion, allowing researchers to measure the glucose infusion rate required to maintain euglycemia—a direct indicator of insulin action.
Approved indications
Common side effects
Key clinical trials
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- The Role of Endocannabinoids in Insulin Production and Action (PHASE1)
- Reprometabolic Syndrome Mediates Subfertility in Obesity (NA)
- Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. (PHASE1)
- VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway (PHASE2)
- Hypoglycemia and Autonomic Nervous System Function-B (PHASE4)
- Studies of Insulin and Glucagon Action in the Liver (PHASE1, PHASE2)
- Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: